Page last updated: 2024-09-04

torcetrapib and Hyperlipoproteinemia Type II

torcetrapib has been researched along with Hyperlipoproteinemia Type II in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B1
Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL1
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI1
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI1
El Harchaoui, K; Kastelein, JJ; Stroes, ES; van der Steeg, WA1
Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T1

Reviews

1 review(s) available for torcetrapib and Hyperlipoproteinemia Type II

ArticleYear
The role of CETP inhibition in dyslipidemia.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:2

    Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Dyslipidemias; Esters; Female; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Male; Quinolines; Sulfhydryl Compounds

2007

Trials

5 trial(s) available for torcetrapib and Hyperlipoproteinemia Type II

ArticleYear
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:2

    Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome

2009
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
    Annals of medicine, 2010, Volume: 42, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography

2010
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16

    Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines

2007
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
    Current medical research and opinion, 2007, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography

2007
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:1

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines

2008